Orders from 100 GBP Free delivery from 205 GBP Ready for pickup dead drop: collect in 5 min

Substances · Benzodiazepines and thienodiazepines

Norflurazepam

C15H10ClFN2O CAS 2886-65-9 Analytical reference material — not for human consumption
Preferred name
Norflurazepam
IUPAC name
7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one
Parent CAS number (reference)
2886-65-9
Molecular formula
C15H10ClFN2O
Molecular weight
288.7 g/mol
InChIKey
UVCOILFBWYKHHB-UHFFFAOYSA-N
PubChem
CID 4540
Source
PubChem
Verified synonyms & catalog abbreviations
N-Desalkylflurazepam Ro 5-3367

Matching Listings in This Store's Catalog

Verified Neurochemical & Toxicological Intelligence

Norflurazepam

Long-Acting Myorelaxant & Anxiolytic GABA-A PAM 1,4-Benzodiazepine
Verified PubChem & CAS Identity C15H10ClFN2O · CAS 2886-65-9 · CID 4540
Calibrated Physical Form Precision Tablets · 1 Tablet = 1 mg
≥98% Analytical Purity Verified 288.7 g/mol
Peer-Reviewed & Agency Citations 2 · verified sources

Receptor Telemetry & Mechanism of Action

GABAₐ α₂/α₃ Anxiolysis & Myorelaxation High PAM
GABAₐ α₁ Hypnotic / Sedative Drive Very High
GABAₐ α₅ Amnestic / Cognitive Modulation High

N-Desalkylflurazepam, the principal long-lived active metabolite of flurazepam, binding broadly across synaptic GABA-A benzodiazepine sites.

Biotransformation & Active Metabolites

Glucuronidated slowly with a documented human elimination half-life of ~40–100 hours.

Temporal Pharmacokinetics

Long-Acting Myorelaxant & Anxiolytic GABA-A PAM — Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam.

  1. Onset 30–90 min
  2. Peak Window 2–4 h
  3. Total Window 10–18 h
  4. Residual / Half-Life 24–60 h residual (T1/2 40–100 h)

Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam.

Quantitative Response Spectrum (Published Literature)

Third-person observational & toxicological brackets reported in scientific and harm-reduction literature — reference telemetry only, never consumption advice.

Threshold
2 mg
Cognitive & Sensory

Subtle threshold receptor activity (Long-Acting Myorelaxant & Anxiolytic GABA-A PAM).

Somatic & Autonomic

Minimal baseline autonomic shift.

Light
2–5 mg
Cognitive & Sensory

Mild, clear-headed expression of primary class profile.

Somatic & Autonomic

Light somatic modulation.

Common Reference
5–10 mg
Cognitive & Sensory

Full characteristic neurochemical and perceptual profile documented in literature.

Somatic & Autonomic

Moderate somatic relaxation, ataxia, or autonomic tone depending on class.

Strong
10–15 mg
Cognitive & Sensory

Pronounced intensity, cognitive/motor impairment, or deep immersion.

Somatic & Autonomic

Marked somatic load and heightened adverse-event sensitivity.

Heavy / Toxic Zone
20+ mg
Cognitive & Sensory

Amnesia, blackout, acute dysphoria, confusion, or anesthetic dissociation.

Somatic & Autonomic

High toxicity zone: severe motor loss, cardiovascular strain, or respiratory hazard.

Interaction Matrix & Critical Contraindications

Critical Hazard — Never Combine

Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl)

Synergistic brainstem respiratory depression causing unconsciousness and fatal respiratory arrest.

Alcohol, GHB/GBL, and Barbiturates

Extreme CNS depression, complete anterograde amnesia, loss of airway reflexes, and fatal aspiration.

Elevated Hazard — Avoid

Dissociatives (Ketamine, 2-FDCK, DCK, O-PCE, MXE)

Unpredictable sedation, severe motor ataxia, blackout, and emesis aspiration hazard.

Caution / Receptor Attenuation

CYP3A4 inhibitors (grapefruit juice, ketoconazole) & Stimulants

CYP3A4 inhibitors prolong plasma half-life; stimulants mask sedation until they wear off.

Structural Isomer & Sibling Comparison

Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam.

Physicochemical Stability & Storage

Form: Precision-pressed 1 mg analytical tablets (1 tablet = 1 mg). · Parent molecule soluble in ethanol, propylene glycol, and DMSO; sparingly soluble in water.

Store sealed in a cool, dry, light-protected container away from humidity.

Cross-Tolerance & Dependence Profile

Complete cross-tolerance across all GABA-A benzodiazepines/thienodiazepines. Rapid physical dependence develops with continuous daily exposure; abrupt cessation after prolonged intake can trigger life-threatening rebound seizures and delirium.

Comprehensive Analytical & Toxicological Monograph

Norflurazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one; CAS 2886-65-9, PubChem CID 4540) is a 1,4-benzodiazepine reference compound (C15H10ClFN2O, 288.7 g/mol) classified pharmacologically as a Long-Acting Myorelaxant & Anxiolytic GABA-A PAM. N-Desalkylflurazepam, the principal long-lived active metabolite of flurazepam, binding broadly across synaptic GABA-A benzodiazepine sites. Glucuronidated slowly with a documented human elimination half-life of ~40–100 hours. In published observational and toxicological literature, threshold response is noted at 2 mg, light range at 2–5 mg, common reference range at 5–10 mg, strong intensity at 10–15 mg, and heavy/adverse territory at 20+ mg, with an onset of 30–90 min, peak window of 2–4 h, and total duration of 10–18 h (24–60 h residual (T1/2 40–100 h)). Gentle per-tablet scale (1 tablet = 1 mg; common literature range 5–10 mg) with warm myorelaxation and a smooth multi-day tail comparable to diazepam/diclazepam. Critical contraindications include Opioids (O-DSMT, tramadol, morphine, oxycodone, fentanyl), Alcohol, GHB/GBL, and Barbiturates.

Chemical Architecture & Structural Profile

Norflurazepam (7-chloro-5-(2-fluorophenyl)-1,3-dihydro-1,4-benzodiazepin-2-one) is a reference compound belonging to the Benzodiazepines and thienodiazepines class, characterized by the molecular formula C15H10ClFN2O and a molar mass of 288.7 g/mol. The parent molecule is indexed under CAS registry number 2886-65-9 and in the NCBI PubChem database as CID 4540 (Standard InChIKey: UVCOILFBWYKHHB-UHFFFAOYSA-N).

Citations

Reference Toxicology & Safety Profile

In documented chemical and harm-reduction literature (PubChem / PsychonautWiki, CC BY 4.0), Norflurazepam is indexed within the Benzodiazepines and thienodiazepines structural group. Triazolo/thienodiazepine reference compound; carries a high risk of synergistic respiratory depression if combined with opioids, alcohol, or other CNS depressants. Standard laboratory handling precautions—including nitrile gloves, eye protection, and local exhaust ventilation—apply whenever handling the reference material.

Citations

Analytical Use & Laboratory Notice

This reference sheet provides chemical, analytical, and toxicological provenance only. The material is strictly not for human consumption, diagnostic, or veterinary use. Research-use labelling does not establish legal status in any jurisdiction.

Citations